MorphoSys, a biotech that has spent much of its three-decade history developing drugs that ended up at other companies via partnerships or licensing deals, is now building up its own pipeline through ...

PLANEGG/MUNICH, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--MorphoSys AG (FSE: MOR; NASDAQ: MOR) and Human Immunology Biosciences, Inc. (HIBio), a South San Francisco-based biotechnology ...

Novartis is building up its pipeline of cancer therapies with the acquisition of MorphoSys, a company whose lead drug is on track for an FDA submission for the treatment of myelofibrosis. But the €2.7 ...

MorphoSys's Licensee Janssen Submits Biologics License Application to U.S. FDA of Tremfya (R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis PLANEGG / MUNICH, GERMANY / ...

MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. Myelofibrosis is a type of blood cancer characterized by the ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Logo is seen at new factory of Novartis in Stein BERLIN (Reuters) -Novartis said on Thursday it has launched a tender ...

Drug maker Novartis is in advanced talks to acquire MorphoSys, a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter said on ...

MorphoSys MOR shares are trading higher on Wednesday after the company announced the completion of enrollment for its Phase 3 MANIFEST-2 study exploring the efficacy and safety of pelabresib. MANIFEST ...

PLANEGG/MUNICH, Germany--(BUSINESS WIRE)-- MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and full year 2021. Jean-Paul Kress continued, “Looking ahead, we are focused on ...

After Novartis reportedly backed out of late-stage talks to acquire Cytokinetics earlier this year, the company appears to still be on the M&A prowl. Novartis is in advanced talks to acquire German ...

Novartis said Monday that it intends to buy MorphoSys for just under $3 billion. The deal will not close. Six months from now, or sooner, Novartis will walk away — slightly embarrassed but otherwise ...